{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:33:59Z","timestamp":1783636439890,"version":"3.55.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/mcg.0b013e318254ebdd","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T07:16:01Z","timestamp":1338362161000},"page":"130-135","source":"Crossref","is-referenced-by-count":55,"title":["Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection"],"prefix":"10.1097","volume":"47","author":[{"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"P\u00e9rez-Aisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Castro-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Almela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Cosme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Modolell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Bory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Fern\u00e1ndez-Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"S\u00e1nchez-Pobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Khorrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Tomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Lamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-11-20210305","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"R3-11-20210305","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2036.2011.04887.x","article-title":"Review article: The effectiveness of standard triple-therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.","volume":"34","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl 1","key":"R4-11-20210305","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1523-5378.2010.00774.x","article-title":"Treatment of Helicobacter pylori infection 2010.","volume":"15","author":"OConnor","year":"2010","journal-title":"Helicobacter"},{"key":"R5-11-20210305","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","article-title":"H. pylori antibiotic resistance: prevalence, importance, and advances in testing.","volume":"53","author":"Megraud","year":"2004","journal-title":"Gut"},{"key":"R6-11-20210305","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2036.2002.01276.x","article-title":"Review article: Helicobacter pylori rescue regimen when proton pump inhibitor-based triple therapies fail.","volume":"16","author":"Gisbert","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-11-20210305","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.3748\/wjg.14.5385","article-title":"Rescue regimens after Helicobacter pylori treatment failure.","volume":"14","author":"Gisbert","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R8-11-20210305","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1523-5378.2005.00324.x","article-title":"Helicobacter pylori rescue therapy after failure of two eradication treatments.","volume":"10","author":"Gisbert","year":"2005","journal-title":"Helicobacter"},{"key":"R9-11-20210305","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","article-title":"Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.","volume":"63","author":"Croom","year":"2003","journal-title":"Drugs"},{"key":"R11-11-20210305","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","article-title":"Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.","volume":"23","author":"Gisbert","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-11-20210305","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","article-title":"Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.","volume":"101","author":"Saad","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R13-11-20210305","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00508-010-1404-3","article-title":"Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.","volume":"122","author":"Li","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"R14-11-20210305","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1572-0241.2007.01500.x","article-title":"Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.","volume":"103","author":"Gisbert","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R15-11-20210305","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.dld.2008.09.013","article-title":"Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.","volume":"41","author":"Di Caro","year":"2009","journal-title":"Dig Liver Dis"},{"key":"R16-11-20210305","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1083-4389.2004.00195.x","article-title":"The TETRA study: a prospective evaluation of Helicobacter pylori test-and-treat strategy on 736 patients in clinical practice.","volume":"9","author":"Gisbert","year":"2004","journal-title":"Helicobacter"},{"key":"R17-11-20210305","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/46.2.283","article-title":"Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristindalfopristin and new quinolones.","volume":"46","author":"Sanchez","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R18-11-20210305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.0083-8703.2006.00375.x","article-title":"7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.","volume":"11","author":"Antos","year":"2006","journal-title":"Helicobacter"},{"key":"R19-11-20210305","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S1590-8658(03)00432-8","article-title":"Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy.","volume":"35","author":"Watanabe","year":"2003","journal-title":"Dig Liver Dis"},{"key":"R20-11-20210305","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2036.2005.02522.x","article-title":"A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses.","volume":"22","author":"Gatta","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-11-20210305","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1542-3565(04)00458-6","article-title":"A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial.","volume":"2","author":"Bilardi","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R22-11-20210305","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.dld.2005.06.002","article-title":"Levofloxacin versus metronidazole-based rescue therapy for H. pylori infection in Japan.","volume":"37","author":"Matsumoto","year":"2005","journal-title":"Dig Liver Dis"},{"key":"R23-11-20210305","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1523-5378.2007.00507.x","article-title":"Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.","volume":"12","author":"Cheng","year":"2007","journal-title":"Helicobacter"},{"key":"R24-11-20210305","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1523-5378.2007.00472.x","article-title":"Levofloxacin vs. ranitidine bismuth citrate-containing therapy after H. pylori treatment failure.","volume":"12","author":"Gisbert","year":"2007","journal-title":"Helicobacter"},{"key":"R25-11-20210305","first-page":"285","article-title":"Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication.","volume":"51","author":"Jung","year":"2008","journal-title":"Korean J Gastroenterol"},{"key":"R26-11-20210305","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkp034","article-title":"Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.","volume":"63","author":"Kuo","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R27-11-20210305","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1523-5378.2006.00432.x","article-title":"A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures.","volume":"11","author":"Lee","year":"2006","journal-title":"Helicobacter"},{"key":"R28-11-20210305","first-page":"19","article-title":"The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication.","volume":"48","author":"Lee","year":"2006","journal-title":"Korean J Gastroenterol"},{"key":"R29-11-20210305","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/gut.2009.198309","article-title":"Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.","volume":"59","author":"Liou","year":"2010","journal-title":"Gut"},{"key":"R30-11-20210305","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-5378.2006.00407.x","article-title":"Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.","volume":"11","author":"Marzio","year":"2006","journal-title":"Helicobacter"},{"key":"R31-11-20210305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1365-2036.2003.01676.x","article-title":"Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial.","volume":"18","author":"Nista","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-11-20210305","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.dld.2007.06.016","article-title":"Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance.","volume":"39","author":"Perna","year":"2007","journal-title":"Dig Liver Dis"},{"key":"R33-11-20210305","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1046\/j.1365-2036.2003.01755.x","article-title":"Randomized study of differentsecond-line therapies for Helicobacter pylori infection after failure of the standard Maastricht triple therapy.","volume":"18","author":"Perri","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-11-20210305","first-page":"96","article-title":"Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication.","volume":"67","author":"Schrauwen","year":"2009","journal-title":"Neth J Med"},{"key":"R35-11-20210305","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2036.2006.02764.x","article-title":"Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.","volume":"23","author":"Wong","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R36-11-20210305","first-page":"131","article-title":"Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.","volume":"19","author":"Zullo","year":"2010","journal-title":"J Gastrointest Liver Dis"},{"key":"R37-11-20210305","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00042737-200111000-00007","article-title":"Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.","volume":"13","author":"Gisbert","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R39-11-20210305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4318\/tjg.2010.0041","article-title":"Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.","volume":"21","author":"Ercin","year":"2010","journal-title":"Turk J Gastroenterol"},{"issue":"suppl 2","key":"R40-11-20210305","first-page":"T2073","article-title":"Experience with high-dose and standard-dose levofloxacin-based therapy of Helicobacter pylori infection with known antimicrobial susceptibility pattern.","volume":"13","author":"Madisch","year":"2007","journal-title":"Gastroenterology"},{"key":"R41-11-20210305","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1523-5378.2010.00788.x","article-title":"The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China.","volume":"15","author":"Gao","year":"2010","journal-title":"Helicobacter"},{"key":"R42-11-20210305","first-page":"409","article-title":"Worldwide H. pylori antibiotic resistance: a systematic review.","volume":"19","author":"De Francesco","year":"2010","journal-title":"J Gastrointest Liver Dis"},{"issue":"suppl 1","key":"R43-11-20210305","first-page":"1715","article-title":"Surveillance of Helicobacter pylori resistance to antibiotics in Europe 2008-2009.","volume":"140","author":"Megraud","year":"2011","journal-title":"Gastroenterology"},{"key":"R44-11-20210305","first-page":"236","article-title":"Resistencia de Helicobacter pylori a diversos antibioticos: un estudio multicentrico espanol.","volume":"34","author":"Perez-Trallero","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"R46-11-20210305","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ajg.2008.87","article-title":"Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.","volume":"104","author":"Rokkas","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R47-11-20210305","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2036.2007.03573.x","article-title":"Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.","volume":"27","author":"Gisbert","year":"2008","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004836-201302000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:27:39Z","timestamp":1618036059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201302000-00011"}},"subtitle":["Time Trends in a Spanish Multicenter Study of 1000 Patients"],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e318254ebdd","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}